Notice is hereby given that the Annual General Meeting of the Company will be held on Monday 14th September, 2026, Through Video Conferencing (VC)/ Other Audio visual means.

APTUS PHARMA LIMITED Date: 21.08.2026 The BSE Ltd Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400001 SECURITY CODE: 544529 SCRIPT SYMBOL: APPL NOTICE OF ANNUAL GENERAL MEETING AND E-VOTING Notice is hereby given that the Annual General Meeting of the Company will be held on Monday, 14th September, 2026 through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”) to transact the business as stated in the Notice of the said Annual General Meeting. The Notice of the Annual General Meeting is also available on the website of the Company at: https://aptus-pharma.com/financial-year-25-26-agm/ Pursuant to Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has provided the facility of remote e-voting through Central Depository Services (India) Limited (CDSL) to enable the Members to cast their votes electronically on the resolutions set forth in the Notice of the Annual General Meeting. Date of completion of sending of Notice of AGM: 21/08/2026 Commencement of E-voting 11/09/2026 (9.00 a.m.) End of E-Voting. 13/09/2026 (5.00 p.m.) Yours faithfully, For Aptus Pharma Limited Tejash Hathi Managing Director DIN: 03151221 Regd. Address: Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logistic Park, Aslali, Daskroi, Ahmedabad, Gujarat – 382427, India Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com CIN: U24230GJ2010PLC061957, GSTIN: 24AAICA7890D1ZM Annual Report (2025 - 26) NOTICE NOTICE is hereby given that the 16th Annual General Meeting ('AGM') of the Members of APTUS PHARMA LIMITED (Formerly known as Aptus Pharma Private Limited) ('the Company') will be held on 14th day of September, 2026 at 11.00 a.m. through Video Conferencing ('VC') / Other Audio-Visual Means ('OAVM'), to transact the following business. The deemed venue for the AGM shall be the Registered Office of the Company at Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logistic Park, Aslali, Daskroi, Ahmedabad, Gujarat – 382427, in accordance with the applicable provisions of the Companies Act, 2013 and the Circulars issued by the Ministry of Corporate Affairs in this regard. ORDINARY BUSINESS 1. Adoption of Financial Statements To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended 31st March, 2026, together with the Reports of the Board of Directors and the Auditors thereon, and, in this regard. 2. Appointment of Director liable to retire by rotation To appoint a Director in place of Mr. Chetan Shantilal Lalseta, (DIN: 02547012), who retires by rotation at this Annual General Meeting in terms of Section 152(6) of the Companies Act, 2013 and, being eligible, offers himself for re-appointment. SPECIAL BUSINESS 3. Approval of Preferential Allotment of Equity shares. To consider and, if thought fit, to pass the following resolution as a SPECIAL RESOLUTION: “RESOLVED THAT pursuant to the provisions of Section 23, 42 and 62(1)(c) and all other applicable provisions, if any, of the Companies Act, 2013 (the “Act”) read with the Rules made thereunder (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force) and provisions of the Memorandum and Articles of Association of the Company, Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, (“SEBI LODR”) and subject to the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“SEBI ICDR Regulations”) the listing agreement entered into by the Company with BSE Limited the “Stock Exchange”) on which the Equity Shares of the Company are listed and in accordance with the provisions of the Foreign Exchange Management Act, 1999 as amended from time to time and the rules, direction, circulars, notifications, regulations and guidelines issued thereunder (“FEMA”) and in accordance with any other applicable rules, regulations, circulars, notifications, clarifications and guidelines issued thereon, from time to time, by the Ministry of Corporate Affairs, the Reserve Bank of India (“RBI”) under FEMA, the Securities and Exchange Board of India (“SEBI”) and/or any other competent authorities, institutions or bodies (hereinafter collectively referred to as the “Regulatory Authorities”), and subject to such conditions as may be prescribed by any one of them while granting any such approval, consent, permission and/or sanction (hereinafter referred to as the “Requisite Approvals”), which may be agreed to by the Board of Directors of the Company (hereinafter www.aptus-pharma.com 01 Annual Report (2025 - 26) called the “Board” which term shall include any committee which the Board may have constituted or hereinafter constitute to exercise its powers including the power conferred by this Resolution), consent of the Members of the Company be and is hereby accorded to the Board for preferential issue of an amount INR 44,88,03,600/- (Indian Rupees forty four crore eighty eight lakhs three thousands and six hundred only) consisting of cash, and accordingly create, issue, offer and allot by way of preferential issue, from time to time, in one or more tranches, 16,02,870 (Sixteen lakhs two thousand eight hundred and seventy only) fully paid up equity shares of face value of INR 10/- each (‘Equity Shares’) at an issue price of INR 280/- (including premium of INR 270/-) per Equity Share of the Company (“Subscription Shares”) which is not less than the price determined in accordance with Chapter V of the SEBI ICDR Regulations (“Floor Price”) as on the Relevant Date (i.e., August 14, 2026, being the date 30 days prior to the date of Annual General Meeting scheduled to be held on September 14, 2026) determined in accordance with applicable law and the valuation report obtained as per the provisions of the Act, the SEBI ICDR Regulations and as required under FEMA, for cash consideration to the “Proposed Allottees” (as mentioned below) on such terms and conditions and in such manner as the Board may think fit in its absolute discretion. The details of Proposed Allotees and the number of Subscription Shares proposed to be allotted to each of them is set forth in the table below: Sr. Name of Proposed Allotees No. of Shares Category# Status 1. Pathik Mayur Parikh 18180 Public Individual 2. Nirav Jagdishchandra Pandya 3600 Public Individual 3. Mayurkumar Jayantilal Gondaliya 5450 Public Individual 4. Mahipalsinh Pravinsinh Zala 1800 Public Individual 5. Gopi Mitesh Parekh 7270 Public Individual 6. Krishna Jayesh Pabari 3600 Public Individual 7. Rahul Pravinchandra Gamot 3600 Public Individual 8. Hetal Rupen Paun 3600 Public Individual 9. Harishkumar Kanjibhai Paun 3600 Public Individual 10. Kavita Ashok Karia 3600 Public Individual 11. Pareshkumar Narandas Kariya 3600 Public Individual 12. Nikitaben Rasheshbhai Kariya 9000 Public Individual 13. Halewood Laboratories Private Limited 36300 Public Corporate 14. Paresh Bharatbhai Manek 17450 Public Individual 15. Vinod Kumar Gupta 9000 Public Individual 16. Purshottamdas Nandlal Kansara 3600 Public Individual 17. Nayana Purushottam Kansara 3600 Public Individual 18. Heena Kandarp Kansara 3600 Public Individual 19. Kandarp Kansara (Huf) 3600 Public HUF 20. Purushottam Kansara (Huf) 3600 Public HUF 21. Ilaben Mahesh Dabhi 3600 Public Individual 22. Bhanumati Kanaiyalal Baldania 1800 Public Individual 23. Baldaniya Mamta Viral 1800 Public Individual 24. Shobhanaben Mukeshbhai Mungalpara 5450 Public Individual 25. Haresh Vrajlal Desai 5450 Public Individual 26. Meghna Bankim Chaudhari 3600 Public Individual 27. Payal Ravikumar Kanani 3600 Public Individual 28. Bhumika Rupesh Aghera 3600 Public Individual www.aptus-pharma.com 02 Annual Report (2025 - 26) 29 [Showing first 8,000 characters — download PDF for full document]